Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(pemphigoid)
7,681 results
  • A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor. [Journal Article]
    Immunol Med. 2020 Jul 07 [Online ahead of print]Sawada K, Sawada T, … Hamaguchi Y
  • Bullous pemphigoid (BP) is a cutaneous autoimmune blistering disorder. Recently, it has been reported that dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with the development of BP (DPP4i-BP). Patients with DPP4i-BP have autoantibodies (autoAbs) preferentially targeting full-length BP180, but not the BP180NC16a domain. In this report, we described a case of anti-BP230 antibody (Ab)-posit…
  • Treatment concerns for bullous pemphigoid in the COVID-19 pandemic era. [Journal Article]
    Dermatol Ther. 2020 Jul 04 [Online ahead of print]Azimi SZ, Firooz A, … Daneshpazhooh M
  • Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic ma…
  • False-Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid. [Journal Article]
    Am J Dermatopathol. 2020 Jun 30 [Online ahead of print]Perry DM, Wilson A, … Maize JC
  • Bullous pemphigoid (BP) is the most common autoimmune blistering disorder of the skin. It is typified by tense blisters with a subepidermal split and mixed dermal inflammatory infiltrate on histology. Biopsy of the perilesional skin for direct immunofluorescence (DIF) has become the gold standard in the diagnosis of BP. Currently there is a pervasive clinical opinion that the lower extremity is a…
  • Challenges of Oral Medicine Specialistsat the time ofCOVID-19 Pandemic. [Journal Article]
    Oral Dis. 2020 Jul 02 [Online ahead of print]Dziedzic A, Varoni EM
  • The novel coronavirus disease 2019 (COVID-19) had caused major disruptions in medical and dental care across the world, affecting secondary care services that had to rapidly adapt to new circumstances. Postponed and delayed oral medicine (OM) care, deferring non-urgent follow-ups in case of patients because of COVID-19 crisis, and limited access to health care, may have lead serious consequences …
  • [Immunomorphology of bullous lesions of the oral mucosa]. [Journal Article]
    Stomatologiia (Mosk). 2020; 99(3):18-21.Rabinovich OF, Babichenko II, Abramova ES
  • The article is devoted to the study of immunohistochemical parameters in patients with bullous lesions of the oral mucosa. The biopsy samples of the oral mucosa were studied in 57 patients, including patients with pemphigoid bullosa (38 people) and pemphigus vulgaris (19 people). The results of immunohistochemical studies indicate the cellular mechanisms of damage to the epithelium, in which IL-1…
  • Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia. [Case Reports]
    Cureus. 2020 May 27; 12(5):e8316.Onukogu I, Ramachandran P, … Joseph G
  • Paraneoplastic disorders are rare multiorgan diseases associated with hematological malignancies such as chronic lymphocytic leukemia (CLL). Some of these paraneoplasms manifest as cutaneous lesions, appearing as a simple rash, ulcers or skin thickening. The pathogenesis for this process has been described as development of certain autoimmune reactions against cell wall antigens and proteins. An …
  • Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis. [Journal Article]
    Clin Ophthalmol. 2020; 14:1619-1627.de la Sen-Corcuera B, Montero-Iruzubieta J, … Merayo-Lloves J
  • CONCLUSIONS: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.
  • Nivolumab-Induced Bullous Pemphigoid Managed without Drug Withdrawal. [Case Reports]
    Indian J Dermatol. 2020 May-Jun; 65(3):214-216.Munera-Campos M, Plana-Pla A, … Ferrándiz C
  • The widespread use of anti-programmed cell death receptor-1 (PD-1) agents has shed light to unusual immune-related adverse effects, especially affecting the skin. We report a case of bullous pemphigoid secondary to nivolumab therapy for metastatic renal carcinoma with a previously unreported complete response to clobetasol ointment alone. The autoimmune blistering disease was successfully treated…
  • Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. [Journal Article]
    Clin Dermatol. 2020 May - Jun; 38(3):384-396.Thomas RM, Colon A, Motaparthi K
  • Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases can be challenging to treat and have significant associated morbidity and mortality, but data supporting the use of rituximab in pemphigoid group diseases remain limited. Although rituximab demonstrates efficacy for clinical im…
  • Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center. [Journal Article]
    Sci Rep. 2020 Jun 17; 10(1):9774.Miyashiro D, Sanches JA
  • Erythroderma is characterized by erythema and scaling affecting more than 80% of the body surface area. It is potentially life-threatening, and diagnosis of the underlying disease is a challenge. Despite laboratory improvements, many cases remain idiopathic. We aimed to analyze clinical and laboratory findings of 309 erythrodermic patients to find clues to the etiologic diagnosis. We performed a …
  • The effects of immunostimulatory herbal supplements on autoimmune skin diseases. [Review]
    J Am Acad Dermatol. 2020 Jun 15 [Online ahead of print]Chakka S, Concha JSS, … Werth VP
  • The use of herbal supplements that promise to improve immune health has gained popularity among dermatology patients. However, there is little to no evidence that herbal supplements improve dermatological conditions. Several in vitro and in vivo studes have shown that Spirulina platensis, Aphanizomenon flos-aqua, Chlorella, Echinacea, and alfalfa activate immune cells, via certain cytokines and c…
  • [Modern diagnostics of autoimmune bullous diseases]. [Review]
    Pathologe. 2020 Jun 15 [Online ahead of print]van Beek N, Schumacher N, … Zillikens D
  • Blisters and erosions of skin and mucous membranes are key features of the clinically heterogeneous group of autoimmune bullous diseases (AIBDs). These can be divided into pemphigoid diseases with autoantibodies against structural proteins of the dermal-epidermal junction, pemphigus diseases with autoantibodies against desmosomal proteins, and dermatitis herpetiformis with autoantibodies against …
  • Emerging treatments for bullous pemphigoid. [Journal Article]
    J Dermatolog Treat. 2020 Jun 13 [Online ahead of print]Garrido PM, Queirós CS, … Filipe P
  • Bullous pemphigoid (BP) is the most common autoimmune blistering disease. It is characterized by an immune response against the hemidesmossomal anchoring proteins BP180 and BP230. BP mainly affects elderly patients, with an increasing incidence over the past two decades. High potency topical and/or systemic corticosteroids as well as immunosuppressants are the current mainstay of treatment. Howev…
New Search Next